GAAP Activators
GAAP, a protein pivotal in regulating intracellular calcium levels, apoptosis, and maintaining Golgi structure, can be influenced by a range of chemical compounds that indirectly impact these processes. Compounds like BAPTA-AM and Ryanodine, which modulate intracellular calcium levels, have the potential to enhance GAAP's functional activity. BAPTA-AM, through its calcium chelation, can modify the calcium signaling pathways, indirectly necessitating an increased activity of GAAP in calcium homeostasis.
Additionally, compounds that disrupt the Golgi structure or affect Golgi function, such as Brefeldin A and Golgicide A, could indirectly enhance the role of GAAP in maintaining Golgi integrity. The alteration in Golgi architecture by these compounds may increase the reliance on GAAP for preserving essential Golgi functions. Furthermore, the use of calcium channel blockers like Nitrendipine, Nifedipine, and Verapamil, which influence calcium dynamics, can indirectly augment GAAP's role in cellular calcium regulation. Cyclopiazonic Acid, another SERCA pump inhibitor, and Dithiothreitol, which affects protein folding in the ER, also play roles in altering the cellular environment in ways that can enhance GAAP's activity in regulating calcium levels and maintaining Golgi structure.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
A calcium chelator, BAPTA-AM can modulate intracellular calcium levels, potentially increasing GAAP activity in maintaining calcium homeostasis. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
By disrupting Golgi architecture, Brefeldin A can enhance the role of GAAP in maintaining Golgi integrity and function. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
Ryanodine modulates calcium release from the endoplasmic reticulum. Altering calcium dynamics can indirectly enhance GAAP's function in calcium regulation. | ||||||
Nitrendipine | 39562-70-4 | sc-201466 sc-201466A sc-201466B | 50 mg 100 mg 500 mg | $109.00 $160.00 $458.00 | 6 | |
A calcium channel blocker, Nitrendipine can influence calcium homeostasis, potentially enhancing GAAP's role in cellular calcium regulation. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, indirectly influencing GAAP's activity in calcium regulation within cells. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
An inhibitor of the SERCA pump, Cyclopiazonic Acid increases cytosolic calcium, potentially enhancing GAAP's regulatory role in intracellular calcium levels. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A disrupts Golgi function, potentially increasing the demand for GAAP activity in maintaining Golgi integrity. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
As a calcium channel blocker, Nifedipine can modulate intracellular calcium levels, indirectly enhancing GAAP's role in calcium regulation. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Another calcium channel blocker, Verapamil can influence calcium dynamics, potentially enhancing GAAP's function in maintaining calcium homeostasis. | ||||||